← Back to patent-cliff list
Azithromycin Sodium Dihydrogen Phosphate (Qilu Pharmaceutical)
Tier C — Watch / tradeAzithromycin Sodium Dihydrogen Phosphate (Qilu Pharmaceutical)
-
Originator
2002
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：50S ribosomal subunit
Indications (approved)：Respiratory tract infection
Regional status
US
-
EU
-
China
Approved
2002-09-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Azithromycin Sodium Dihydrogen Phosphate (Qilu Pharmaceutical)?
Approved indications include: Respiratory tract infection.
When does the Azithromycin Sodium Dihydrogen Phosphate (Qilu Pharmaceutical) patent expire?
No public expiry year is available for Azithromycin Sodium Dihydrogen Phosphate (Qilu Pharmaceutical) yet; this page updates once verified.
How do I get a quote for Azithromycin Sodium Dihydrogen Phosphate (Qilu Pharmaceutical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-04